Alma UK announces strategic collaboration with Prollenium to distribute Revanesse® and SoftFil®️ in the UK.
Alma UK, a leading provider in advanced medical aesthetics solutions, is pleased to announce an exciting new collaboration with Prollenium Medical Technologies, the innovators behind the behind Revanesse®, the renowned dermal fillers collection.
From September 1, 2024, Alma UK will be the exclusive distributor of Revanesse® and SoftFil®️ across the United Kingdom.
The new partnership represents a significant milestone in the aesthetics industry, merging Alma’s award-winning expertise in energy-based devices with Revanesse’s groundbreaking injectable treatments, ensuring optimal outcomes for clinics and their patients. As part of this strategic alliance, the Prollenium UK team will now join Alma UK, forming the new Alma Injectables Division in the UK. This division will focus on providing comprehensive solutions to clinics, underpinned by the same customer-centric approach that has driven both Alma and Prollenium to the forefront of the industry.
The addition of Revanesse® and SoftFil® to Alma’s extensive range of products underscores the company’s commitment to providing cutting-edge, scientifically-backed technologies.
Revanesse® is renowned for its innovative formulation, and spherical particles which offers smoother, more natural results with less swelling and discomfort, setting a new standard in dermal fillers.
“By partnering with Alma UK, we’re combining our strengths to offer clinics a powerful synergy of advanced injectables and cutting-edge energy-based technologies, ultimately enhancing patient outcomes and clinic success.”
Ario Khoshbin,
CEO of Prollenium.
In a head-to-head clinical trial, a higher percentage of subjects treated with Restylane® reported pain at the injection site compared to those treated with Revanesse® Ultra. Similar findings were noted for swelling, with more subjects in the Restylane® group experiencing injection site swelling than those in the Revanesse® Ultra group1. This level of performance exemplifies the advanced technology and research behind the Revanesse® collection, which includes a comprehensive range of dermal fillers such as Revanesse® Revise, Revanesse® Kiss, Revanesse® Ultra, Revanesse® Contour, Revanesse® Outline, and Revanesse® Shape.
To ensure that clinics are fully equipped to utilise these new products, Alma will provide state-of-the-art training and ongoing support through Harley Academy as well as their renowned training facilities in London, which offer stunning views of St Paul’s Cathedral. Alma’s Global Academies and innovative UK Clinic Marketing Accelerator Programme will further support clinics in achieving exceptional patient outcomes and business growth.
“The strategic partnership with Prollenium and the introduction of Revanesse® will allow us to bring a new era of innovation to the medical aesthetics industry. Together, we are empowered to pioneer cutting-edge solutions by delivering high-end injectable products and proprietary technologies,”
He continued, “The UK is a strategic territory for Alma, and we are excited to bring to the kingdom a high-end injectables collection that will increase patient lifetime value and completely redefine the experience of beauty-seekers in the territory”
Lior Dayan,
CEO of Alma and Sisram.
About Prollenium Medical Technologies
Prollenium Medical Technologies, founded in 2002 by Ario Khoshbin, is a leading Canadian company in aesthetic medicine. Known for its Revanesse® Hyaluronic acid dermal fillers, ProlleniumTM acquired SoftFil® in 2023, adding micro-cannulas and post-procedure skincare to its offerings. With ISO 13485:2016 certification and FDA, Health Canada, and CE approvals, ProlleniumTM sells in over 70+ countries worldwide. The company’s advanced Canadian facilities were the first in North America to produce HA fillers, reflecting its dedication to innovation and quality.
Find out More about Prollenium
